Specialty CDMO making contrast-media intermediates, high-intensity sweeteners, and pharma intermediates/APIs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 1 | 10 | 35 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1.1k | 1.2k | 1.3k |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 21 | 42 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 251 | 239 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1.1k | 1.4k | 1.5k | 1.6k |
| AssetsFixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 303 | 316 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 159 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 210 | 252 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 855 | 771 |
| Total Assets | 364 | 534 | 713 | 862 | 1.1k | 1.4k | 1.5k | 1.6k |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 122 | 137 | 146 | 142 | 241 | 46 | 334 |
| Cash from Investing | -45 | -61 | -76 | -147 | -264 | -35 | -276 |
| Cash from Financing | -72 | -21 | -56 | -4 | -2 | -19 | -31 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | -34 | 115 |
| FCF Margin | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (41.1×) and current (35.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 15.3% growth and a 36× exit, ₹513 only delivers your return if you pay ₹463. The price is currently baking in 17% growth.
EPS grows 15.3%/yr for 5 years, then fades to 6% over 2, exits at 36×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 15.3% | 16.49 |
| FY28 | 15.3% | 19.01 |
| FY29 | 15.3% | 21.92 |
| FY30 | 15.3% | 25.27 |
| FY31 | 15.3% | 29.14 |
| FY32 | 10.7% ·fade | 32.24 |
| FY33 | 6.0% ·fade | 34.18 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.